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Abstract: In this study we investigated the structure-activity relationships by using the Electron- Topological Method 
(ETM) for a class of AChE inhibitors related to tacrine (9-amino-1,2,3,4-tetrahydroacridine) and 11 H-Indeno-[1,2-b]-
quinolin-10-ylamine that tetracyclic tacrine analogues, a drug currently in use for the treatment of the AD. Molecular 
fragments being specific for active and inactive compounds were revealed by using ETM. The result of testing showed the 
high ability of ETM in predicting the activity and inactivity in investigated series. 
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INTRODUCTION 
  Alzheimer’s disease (AD) is a progressive neurodegen-
erative illness that affects up to 5% of people over 65 years, 
rising to 20% of those over 80 years [1]. The study of new 
agents useful to treat AD is one of the most active research 
fields in both pharmaceutical industry and academia. AD is a 
progressive neurodegenerative syndrome associated with 
aging leading to the most common form of senile dementia. 
The disease is characterized by the presence of some neuro-
pathological markers detected in the brain of AD patients, 
which are the -amyloid (A) plaques and the neuro-
fibrillary tangles. A pathogenic role is ascribed to these le-
sions, and many research programs focused on drugs able to 
modify the course of the disease are targeting both their for-
mation and neuro-toxicity [2]. 
  One of the few undisputed evidences in the neuropathol-
ogy of the Alzheimer's disease is the loss of cholinergic neu-
rons occurring in different areas of the central nervous sys-
tem (CNS), mainly the cerebral cortex and hippocampus. 
This loss of cholinergic innervations is the ultimate cause of 
the cognitive and behavioral abnormalities that characterize 
AD, and it is not a surprise that the early pharmacological 
approaches to the treatment of the AD patients were aimed at 
increasing the availability of the cholinergic neuro-trans-
mitter acetylcholine (ACh) [3]. On this basis, the cholinergic 
hypothesis became the leading strategy for the development 
of AD drugs [4, 5]. Tacrine was the first acetylcholinesterase 
(AChE) inhibitor launched in 1993 as the first drug for the 
symptomatic treatment of AD drug [6]. 
  In this study we investigated the structure-activity rela-
tionships by using the Electron- Topological Method [7-17] 
for a class of AChE inhibitors related to tacrine (9-amino-1, 
2, 3, 4-tetrahydroacridine) analogues [6] and 11 H-Indeno- 
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[1,2-b]-quinolin-10-ylamine analogues that tetracyclic tacrine 
analogues [18, 19], a drug currently in use for the treatment 
of the AD. The series under investigation were given in Table 
1 and their common skeletons were shown in the Scheme 1. 
  All conformational and quantum-chemical data were 
obtained by means of the MMP2 method of the molecular 
mechanics and a semi-empirical quantum-chemistry method 
known as 1. Activity features’ selection has been carried 
out by means of the ETM-software. To have more stable 
activity features, every active compound was used as a tem-
plate for comparison with the rest of compounds. As a result 
of this comparison, activity features (pharmacophores) Ph1, 
Ph2 and Ph3 were revealed. To decide which of pharma-
cophores is better, each inactive compound was used as a 
template for comparison with the rest of compounds. So, 
inactivity features (anti-pharmacophores) APh1, APh2 and 
APh3, were revealed also to complete the system for the 
AChE inhibitory activity prediction. 
MATERIALS AND METHODS 
  There are many methods for studying Structure-Activity 
Relationships (SAR), and all of them have some disadvan-
tages. The purpose of the ETM [7-17] is to overcome the 
molecular descriptions of the previously developed SAR 
methods. 
  To apply ETM, activity data (qualified at least as being 
active or inactive) and structures of compounds are taken 
from outer databases or literature. Ideally, half of the mole-
cules should be active [20]. The following steps were applied 
for the ETM procedure (see Fig. 1) [8, 10, 11]: 
1)  Molecular mechanics conformational analyses on 
each of molecules were carried out [21]. 
2)  The electronic structures of each of these conforma-
tions were calculated with semi-empirical method 
known as 1. 76    The Open Medicinal Chemistry Journal, 2008, Volume 2  Saracoglu and Kandemirli 
Table 1.  The Series of Chemical Compounds Under Investigation 
 
Skeleton I 
Compound R  R1 R 2 R 3 R 4 R 5 X  Activity, (IC50 μM) 
1  H  Me H – – – –  8.1 
2  H H  Me  –  –  –  –  0.10 
3  H Cl  H  –  –  –  –  0.55 
4  H H  Cl  –  –  –  –  0.0099 
5  H NO2 H  – – – –  3.0 
6  H H  NO2 –  –  –  –  0.028 
7  H H  O-Me  –  –  –  –  0.35 
8  H NH2 H  – – – –  3.8 
9  H H  F  –  –  –  –  0.087 
10  H Cl  Cl  –  –  –  –  0.47 
11  H O-Me  O-Me  – –  – –  5.2 
12  CH2-Ph  Me H – – – –  3.7 
13  CH2-Ph H  Me  –  –  –  –  0.75 
14  CH2-Ph H  Cl  –  –  –  –  0.17 
15  CH2-Ph NO2 H  – – – –  1.6 
16  CH2-Ph H  NO2 –  –  –  –  4.8 
17  C7H15  Me H – – – –  0.39 
18  C7H15 H  Me – – – –  0.13 
19  C7H15 H  Cl – – – –  0.013 
20  C7H15 H NO2 –  –  –  –  0.29 
21  C7H15 H  O-Me  – – – –  0.46 
22  C7H15 H  F  – – – –  0.045 
23  H H  H  –  –  –  –  0.25 
Skeleton II 
Compound R  R1 R 2 R 3 R 4 R 5 X  Activity, (IC50 μM) 
24  H H  H  H  H  H  –  0.68 
25  H NO2 H H H H –  >100 
26  H NO2 H H H H –  5.9 
27  H H  NO2 H  H  H  –  67.5 
28  H H  NH2 H  H  H  –  29 
29  H  H  Cl H H H –  6.5 
30  H H  F  H  H  H  –  1.2 
31  H H  H  O-Me  H  H  –  1.6 
32  H  H  H  H O-Me H  –  6.5 
33  H  H  H  H  H O-Me –  4.3 
34  H H  H  Me  H  H  –  3.9 
35  H H  H  H  H  Me  –  4.6 
36  H H  H  H  F  H  –  0.43 
37  H  H  H  H Cl H –  5.4 
38  CH2-Ph H  H  H  H  H  –  7.1 
39  Me H H  H  H  H  –  1.3 
40  C7H15 H  H H H H –  4.3 
Skeleton III 
Compound R  R1 R 2 R 3 R 4 R 5 X  Activity, (IC50 μM) 
41  – –  –  –  –  –  CH2-CH2 2.98 
42  – –  –  –  –  –  OCH2 245 
43  – –  –  –  –  –  SCH2 18.58 
44  – –  –  –  –  –  –  11.48 The Investigation of Structure-Activity Relationships of Tacrine Analogues  The Open Medicinal Chemistry Journal, 2008, Volume 2    77 
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Scheme 1. Common molecular skeletons of tacrine and 11H-
indeno-[1,2-b]-quinolin-10-ylamine tetracyclic tacrine analogues. 
 
3)  Corresponding electronic and geometric parameters 
were arranged in a matrix n x n (n is the number of) 
called ETMC. 
4)  Series studied were divided as active, inactive and 
low active molecules. 
5)  Template molecules (the most active one) that are to 
be compared with the rest of molecules in the series 
are selected for active and inactive groups. 
6)  Structural fragments common to all active molecules 
are searched for through the comparison of all 
ETMCs with the template ETMC selected. Taken into 
account some limiting values were ± 0.05 for 1 and ± 
0.15 for  2. A probabilistic criterion, P which was 
calculated by the following formula, is commonly 
used in structural methods for estimate activity frag-
ment in a series under study. 
P= (nA+1)/ (nA+nIA+2) 
where nA, nIA are numbers of active/inactive molecules, re-
spectively, which contain the fragments 
RESULTS AND DISCUSSION 
  In this study, we used optimized geometry data and elec-
tronic characteristics to form ETMCs for all compounds in a 
series of to tacrine (9-amino-1, 2, 3, 4-tetrahydroacridine) 
analogues [6] and 11 H-Indeno-[1,2-b]-quinolin-10-ylamine 
analogues [18, 19] including 44 molecules. Effective charges 
on atoms are shown on diagonal elements, bond characteris-
tics and optimized distances are represented on non diagonal 
elements. 
     ETMC
Construction
Local DB
Initial Settings for a
Fragment Selection
    The Search for
Common Fragments
Statistical Estimations
    System for the
activity quantititative
   and qualitative
 prognostications
 
Fig. (1). Common scheme of the ETM. 
 
  According to the activity level, molecules under study 
(44 in all) [6, 18, 19] were divided into 3 groups: 
1.  Active compounds (20 mol. with IC50  1.3); 
2.  Low active compounds (4 mol. with 1.3 > IC50 < 3.7); 
3.  Inactive compounds (20 mol. with IC50  3.7) com-
pounds. 
  The parameters responsible for the activity form a matrix 
called electron topological sub matrix of activity (ETSA), 
calculated from an ETMC that represents one of the most 
active compounds (“a template” for comparison). 
Determination of Pharmacophores Features 
  For each template compound, its ETMC was compared 
with the ETMCs of the rest of the compounds in both series. 
The comparison resulted in a few common structural frag-
ments for the two cases. The fragments were found as sub-
matrices of the corresponding template ETMCs (i.e. elec-
tron-topological sub-matrices of contiguity, or ETSCs, for 
short). 
 Compound  4 taken as template compound from active 
ones was accepted active one and from the template com-
pound 4 an activity feature 1 (or pharmacophore, Ph1) were 
found. It’s given in Fig. (2), alone with the corresponding 
ETSCs, which describe electronic-topological characteristics 
of the fragments (see Fig. 2). 
  In the matrices, the effective charges on atoms (local 
atomic characteristics, Qi) were chosen for diagonal ele-
ments, while at place of non-diagonal elements representing 
inter-atomic characteristics, there are either Wiberg’s indices 
[22], (Wij, for bonds) or optimized distances (Rij, in Å, for 
chemically non-bonded pairs of atoms). 10-12 pairs of at-78    The Open Medicinal Chemistry Journal, 2008, Volume 2  Saracoglu and Kandemirli 
oms are chemical bonded and bond order is 1.01 . The dis-
tance between C12 and N15 atom is 2.81 Å. 
  Sub-matrices given in Fig. (2) were found after setting 
some allowable limits for the comparison of matrix ele-
ments. For both series, the limits are 1= 0.05 for diagonal 
elements of the ETMCs and 2= 0.15 for their off-diagonal 
elements comparison. The pharmacophores found from the 
ETM-calculations are realized in all (15) active compounds. 
Statistical estimates for the pharmacophores are given in 
Table 1. 
  An activity feature Ph1 is shown along with its ETSA of 
the order 8x8 (see Fig. 2). Only its upper triangle is given 
because of the symmetry of bounds. The pharmacophore was 
found in 15 of 20 active compounds, nA, and it was found in 
2 of 20 inactive compounds, nIA. Thus, the probability PA of 
its realization in this class is about 0.84. As seen from the 
pharmacophore structure, the active feature 1, Ph1, consists 
of the 8 atoms (1, 5, 6, C9, C10, C12, C13 and N15). 
 Compound  6 was chosen as template and compared the 
rest of the molecules in the series. Pharmacophores 2, Ph2, 
were found in 13 of 20 active compounds having the prob-
ability PA = 0.88 as seen in Fig. (3). 
 Compound  19 was chosen as template and the active fea-
ture 3, Ph3, is formed by 4 different atoms and statistical 
estimates for the pharmacophores are given in see Fig. (4). 
Determination of Anti-Pharmacophores Features 
  Anti-pharmacophores, alone with pharmacophores, are 
also of interest for the researches as those parts of molecules 
that are responsible for the considerable decrease or com-
plete loss of the activity in view. To find anti-pharmaco-
phores, inactive compounds 25, 27 and 42 were selected as 
template compounds (their structures are given in Fig. 5). 
Again, both protonated and unprotonated forms of com-
pounds 25, 27 and 42 were studied. As an example, APh1, 
APh2 and APh3 anti-pharmacophores are shown in the fig-
ure by their numbers, while corresponding sub-matrices are 
given nearby. 
  The anti-pharmacophore APh1, APh2 and APh3 (see Fig. 
5) consisting of 5 atoms, enters the structures of 15 inactive 
molecules and are found 2 active compounds (see Fig. 5). 
The probability is 84%, because they are found in 15 from 
20 inactive molecules in total. 
  When comparing the structures of the pharmacophores 
and anti-pharmacophores, one can pay attention to the differ-
ences in their spatial and electron characteristics. Thus, 
pharmacophores and anti-pharmacophores can play their role 
in the activity prediction only if both types of fragments par-
ticipate in the process of prognosis. Thus, the set of activ-
ity/inactivity fragments found as the result of this study 
forms a basis for a system of the Human AChE activity bind-
ing affinity prediction. 
  As seen from Fig. (6), the pharmacophores Ph1-Ph3 and 
anti-pharmacophores APh1-APh3 found as the result of the 
ETM application were used as a basis for a system formation 
capable of the thiobenzamide and quinolizidine analogues 
activity prediction. 
CONCLUSION 
  A series of tacrine and 11 H-Indeno-[1,2-b]-quinolin-10-
ylamine compounds demonstrating Human AChE activity 
binding affinity is studied by means of the ETM, which takes 
into account both structural and electronic characteristics of 
molecules. Based on pharmacophores and anti-pharmaco-
C1 C 5 C 6 C 9 C 10 C 12 C 13 N 15 
0.05 2.31  1.29  4.00  3.60  4.88  6.36  2.81 
 0.15  1.25  2.25  2.66  4.17  4.77  3.58 
   -0.04  2.66  2.34  3.74  5.03  2.37 
    0.15  1.32  2.49  2.54  3.57 
     - 0 . 0 8   1.01  2.89  2.35 
      0.03  2.50  2.81 
1= ± 0.05,  2= ± 0.15    0.03  5.05 
  nA/ nIA= 15/2, PA = 0.84      -0.25 
Fig. (2). ETSC and corresponding structure of the pharmacophore Ph1 found relative to active compound 4. 
C1 C 8 C 9 C 10 C 11 C 13 N 15 H 17 
0.03 2.38 4.00 3.60 5.50 6.36 2.82 3.77 
  0.17 2.31 1.44 3.74 4.23 1.10 2.04 
    0.16 1.31 1.01 2.54 3.57 3.89 
    -0.08  2.52 2.89 2.35 2.55 
     -0.01  1.02 4.87 4.99 
      0.02  5.05  4.88 
 1= ± 0.05,  2= ± 0.15    -0.26  0.97 
0.12 
 
nA/ nIA= 13/1, PA = 0.88     
 
Fig. (3). ETSC and corresponding structure of the pharmacophore Ph2 found relative to active compound 6. The Investigation of Structure-Activity Relationships of Tacrine Analogues  The Open Medicinal Chemistry Journal, 2008, Volume 2    79 
phores calculated by the ETM-software as sub-matrices con-
taining important spatial and quantum chemistry characteris-
tics, a system for the activity prognostication is developed. 
The comparison of pharmacophores determined relative to 
the neutral and protonated forms was in favor of protonated 
forms as to their statistical estimates. The system was tested 
on a few compounds with molecular skeletons other than 
those that were characteristic of the training sets which allow 
to identify the presence/absence of the Human AChE activity 
binding affinity (with probabilities 84-89%) in molecules 
with diverse structures and predicting the level of the activ-
ity. 
  The initial data analysis reveals the intimate relation of 
the activity exhibition by compounds to their spatial and 
electronic states. Any changes in the values of the matrices 
C8 C 10 C 19 C 20 
0.18 1.48 4.41 5.30 
 -0.05  4.89  5.58 
   0.02  1.02 
    0.02 
 
 
1= ± 0.04, 2= ± 0.12 
LA/ LIA= 15/1, Pa = 0.89 
 
Fig. (4). ETSC and corresponding structure of the pharmacophore Ph3 found relative to active compound 19. 
 
C1 C 2 C 9 C 12 C 19 
0.07  1.47 3.99 5.32  7.58 
  0.03 4.81 6.14  8.30 
   0.16  1.08  3.60 
     -0.01  2.33 
0.01 
 
1= ± 0.05, 2= ± 0.15 
LIA/LA= 15/2, Pia = 0.84 
 
 
a 
 
 
 
C1 C 2 C 9 C 12 C 19   C 2 C 11 C 13 H 16 C 19 
0.03 1.56  3.98 5.31  7.59   -0.01 6.11 7.12 3.87  8.38 
 0.01  4.77  6.11  8.29    0.03  1.34  5.55  2.34 
   0.15  1.08  3.61      0.03  5.84  1.42 
1= ± 0.05, 2= ± 0.15  0.01 2.31    1= ± 0.04, 2= ± 0.13  0.11 6.79 
LIA/LA= 15/2, Pia = 0.84    0.01   L IA/LA= 15/2, Pia = 0.84  0.01 
b   c 
Fig. (5). ETSC and corresponding structure of the pharmacophore: (a) APh1; (b) APh2; and (c) APh3 found relative to inactive molecule 25, 
27, and 42. 80    The Open Medicinal Chemistry Journal, 2008, Volume 2  Saracoglu and Kandemirli 
that excel the limits allowed cause diminishing or complete 
loss of the activity. 
  The system for the Human AChE activity prediction is 
supposed to be used for new potent drugs synthesis which 
will make the screening of the new potential drugs’ design 
easy and effective. 
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Fig. (6). Frequency of the fragments’ occurrences in the compounds studied: for Pharmacophores Ph1, Ph2 and Ph3; for anti-
pharmacophores APh1, APh2 and APh3. 